Introduction to Antibiotic Susceptibility/Resistance

In recent years, live bacterial therapeutics has become a new class of regulatory approach for treating various human and animal diseases. For instance, the development of novel next-generation probiotics (NGPs) can be widely used for skin disease control with a high therapeutic effect and improved safety. However, pilot studies have indicated that most NGPs strains are susceptible to certain types of antibiotics, such as ampicillin and gentamicin, and they are not be easily eliminated if they harm the host. Moreover, the antibiotic resistance of these NGPs may subsequently spread to specific pathogenic microorganisms. As a result, a panel of assays, including antibiotic susceptibility/resistance testing, have been generated for measuring the pathogenic bacteria in clinical samples.